These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28140713)

  • 1. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
    Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
    Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
    Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
    Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
    Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
    Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
    Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
    Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
    Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
    World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
    Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
    Tataranni T; Mazzoccoli C; Agriesti F; De Luca L; Laurenzana I; Simeon V; Ruggieri V; Pacelli C; Della Sala G; Musto P; Capitanio N; Piccoli C
    Stem Cell Res Ther; 2019 Jun; 10(1):171. PubMed ID: 31196186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
    Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
    Pullarkat V; Sehgal A; Li L; Meng Z; Lin A; Forman S; Bhatia R
    Leuk Res; 2012 Aug; 36(8):966-73. PubMed ID: 22502920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
    Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
    Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D
    Haematologica; 2010 Aug; 95(8):1308-16. PubMed ID: 20534700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
    Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
    Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
    Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
    Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
    Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
    Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
    Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of celecoxib and doxorubicin increases growth inhibition and apoptosis in acute myeloid leukemia cells.
    Chen C; Xu W; Wang CM
    Leuk Lymphoma; 2013 Nov; 54(11):2517-22. PubMed ID: 23452119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
    Tataranni T; Agriesti F; Mazzoccoli C; Ruggieri V; Scrima R; Laurenzana I; D'Auria F; Falzetti F; Di Ianni M; Musto P; Capitanio N; Piccoli C
    Br J Haematol; 2015 Jul; 170(2):236-46. PubMed ID: 25825160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
    Zhang L; Wang Z; Khishignyam T; Chen T; Zhou C; Zhang Z; Jin M; Wang R; Qiu Y; Kong D
    Biomed Pharmacother; 2018 Jul; 103():1069-1078. PubMed ID: 29710665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
    Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
    Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.